NCT00246675

Frusemide Infusion for the Prevention of Deterioration in Renal Function Post Cardiac Surgery.

Frusemide Infusion for the Prevention of Deterioration of Renal Function in Post Cardiac Surgery

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Melbourne Health · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the project is to test whether or not the commonly used medication frusemide, given after heart surgery, and aiming to increase urinary output can have an effect on kidney function.

Detailed description

All patients will receive standard supportive care based on current established management practice of cardio-thoracic patients. The only difference in treatment will be the randomisation of patients to receive/not receive protocolised administration of frusemide targeting a urine output. There will be 2 groups of patients. The control group-which will receive frusemide bolus doses if required as determined by the surgeon/consultant physician. The frusemide infusion group-which will be monitored to achieve a trial specified hourly urine output target range of 1-2mls/kg/hour. In order to achieve this target the patient may need to receive a loading dose of frusemide and may also then require a frusemide infusion. The aim will be to maintain the urine output within the target range for the first 48 hours after cardiac surgery.

Conditions

• Renal Impairment After Cardiac Surgery

Interventions

Type	Name	Description
DRUG	Frusemide

Timeline

• First posted: 2005-10-31
• Last updated: 2015-04-27

Locations

1 site across 1 country: Australia